Inflammatory mediators pathway

The "Inflammatory mediators pathway" is not a single molecular target but rather refers to a complex network of signaling events involving numerous molecules that regulate inflammation. These include pro-inflammatory cytokines (like IL‑1β, IL‑6, TNF‑α), lipid-derived mediators (prostaglandins and leukotrienes), vasoactive amines (histamine and serotonin), peptide mediators (bradykinin), chemokines, adhesion molecules, and key intracellular signaling proteins such as NF‑κB and STATs. The coordinated action of these components orchestrates immune cell recruitment, vascular changes like vasodilation and increased permeability, pain induction, fever generation, tissue repair processes—and when dysregulated—chronic diseases including autoimmunity and cancer. Because it encompasses many distinct molecular entities rather than one defined druggable target or receptor/enzyme/transporter class molecule[1][2][4], it is not considered an individual therapeutic target but instead describes the broader biological context in which many validated drug targets operate. Summary: The "Inflammatory mediators pathway" is not itself a canonical molecular target but an umbrella term for interconnected biochemical routes controlling inflammation via diverse effectors. For structured data purposes it should be flagged as incorrect/not-a-target; information about therapeutic intervention should focus on its constituent molecules like cytokines or enzymes[1][2][4].

Other names

Inflammatory signaling pathwaysInflammation pathwayPro-inflammatory mediator pathwaysInflammatory response pathway